uploads/2018/12/dna-1811955_640.jpg

How’s Seattle Genetics Positioned?

By

Updated

Company overview

Seattle Genetics (SGEN) is a biotechnology company with a focus on developing and bringing to market targeted therapies for cancer. Its antibody-drug conjugate technology makes use of the targeting ability of monoclonal antibodies to deliver cell-killing agents to cancer cells. Its current product on the market, Adcetris, is used for treating different types of lymphomas.

Article continues below advertisement

Top line

Seattle Genetics generated total revenues of $169.42 million in the third quarter of 2018 as compared with $135.29 million in the comparable period of 2017.

The company generates revenues from product sales, collaboration and licensing agreements, and royalties. Its Adcetris product sales surged from $79.18 million in the third quarter of 2017 to $126.98 million in the third quarter of 2018 due to higher volumes and label expansions. Royalty revenues increased from $16.67 million in the third quarter of 2017 to $22.66 million in the third quarter of 2018. Seattle Genetics’ collaboration and license agreement revenues, on the other hand, decreased from $39.44 million in the year-ago period to $19.79 million in the third quarter of 2018.

For fiscal 2018 and 2019, Seattle Genetics is expected to generate revenues of $643.72 million and $864.94 million, respectively, as compared with revenues of $482.25 million in fiscal 2017. In comparison, the fiscal 2018 revenues of peers Amgen (AMGN), Gilead Sciences (GILD), and Eli Lilly & Co (LLY) are expected at $23.36 billion, $21.77 billion, and $24.42 billion, respectively.

We take a look at Seattle Genetics’ operational performance in the next part.

Advertisement

More From Market Realist